MP566SERUM CHROMIUM LEVEL IN CHRONIC PERITONEAL DIALYSIS PATIENTS IS HIGHER THAN IN CHRONIC HEMODIALYSIS PATIENTS

Beta-2 microglobulin (B2M) is amyloidogenic in long-term hemodialysis patients, with amyloid deposition manifesting as lytic bone lesions, carpal tunnel syndrome, destructive arthropathies, tenosynovitis, and pathologic fractures. To study the behavior of this protein in the peritoneal dialysis population, serum levels of B2M from 14 chronic peritoneal dialysis (CPD) patients (4IPD, 10 CAPD) were compared to those of 15 chronic hemodialysis patients, and peritoneal clearances were measured in 9 CAPD patients. Standard cuprophan dialyzers were used for hemodialysis. Serum B2M levels were significantly lower in the peritoneal dialysis group (mean ± SD 73.2 ± 20.9 mg/L) than in the hemodialysis group (100.3 ± 24.7 mg/L, p < .004). When CAPD patients alone were compared to the hemodialysis patients, lower serum B2M levels were again apparent, with mean 68.7 ± 16.4 mg/L (p ≤ .002). Mean serum B2M in IPD patients (84.6 ± 28.9 mg/L) did not differ statistically from either the CAPD or the hemodialysis group. Peritoneal clearance of B2M, urea nitrogen, and creatinine over a 6 h exchange were obtained in 9 CAPD patients without peritonitis. Mean clearance (±SD) of B2M was 0.9 ± 0.4 ml/min/1.73 m2, urea nitrogen 5.3 ± 0.3 ml/min/1.73 m2, and creatinine 4.2 ± 0.8 ml/min/1.73 m2. Mean loss of B2M via the peritoneal cavity was 19.9 ± 6.6 mg/2 L-exchange/1.73 m2 (range 7.7 to 26.2 mg/2 L-exchange/1.73 m2). Decreased serum B2M in peritoneal dialysis patients is consistent with increased clearance by the peritoneal membrane versus standard cellulosic hemodialysis membranes. Whether use of CPD rather than hemodialysis can prevent or even treat dialysis-associated amyloidosis (AB2M) remains speculative.

Download Full-text

Study on cellular immunity in chronic hemodialysis patients and continuous ambulatory peritoneal dialysis patients

Journal of Japanese Society for Dialysis Therapy ◽

10.4009/jsdt1985.19.1093 ◽

1986 ◽

Vol 19 (12) ◽

pp. 1093-1098

Author(s):

Yoshio Maruyama ◽

Kenichi Tsumatani ◽

Yoshiteru Kaneko ◽

Akira Moriya ◽

Kazuo Kubota ◽

...

Keyword(s):

Peritoneal Dialysis ◽

Continuous Ambulatory Peritoneal Dialysis ◽

Cellular Immunity ◽

Hemodialysis Patients ◽

Chronic Hemodialysis ◽

Dialysis Patients

Download Full-text

Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfp067 ◽

2009 ◽

Vol 24 (6) ◽

pp. 1962-1969 ◽

Cited By ~ 33

Author(s):

A. Y.-M. Wang ◽

C. W.-K. Lam ◽

M. Wang ◽

I. H.-S. Chan ◽

S.-F. Lui ◽

...

Keyword(s):

Peritoneal Dialysis ◽

Left Ventricular ◽

Serum Biomarkers ◽

Chronic Peritoneal Dialysis ◽

Dialysis Patients ◽

Diagnostic Potential

Download Full-text

Incidence, Microbiological Spectrum and Outcomes of Infective Peritonitis in Chronic Peritoneal Dialysis Patients

Journal of Clinical Nephrology and Renal Care ◽

10.23937/2572-3286.1510049 ◽

2020 ◽

Vol 6 (1) ◽

Author(s):

Sood Vivek ◽

Kumar Vivek ◽

Ramachandran Raja ◽

Gupta Shefali ◽

Gautam Vikas ◽

...

Keyword(s):

Peritoneal Dialysis ◽

Chronic Peritoneal Dialysis ◽

Dialysis Patients

Download Full-text

The Diagnosis of Protein Energy Wasting in Chronic Peritoneal Dialysis Patients Is Influenced by the Method of Calculating Muscle Mass. A Prospective, Multicenter Study

Frontiers in Medicine ◽

10.3389/fmed.2021.702749 ◽

2021 ◽

Vol 8 ◽

Author(s):

Cristina Techy Roth-Stefanski ◽

Naiane Rodrigues de Almeida ◽

Gilson Biagini ◽

Natália K. Scatone ◽

Fabiana B. Nerbass ◽

...

Keyword(s):

Peritoneal Dialysis ◽

Muscle Mass ◽

Chronic Peritoneal Dialysis ◽

Dialysis Patients ◽

Protein Energy Wasting ◽

Protein Energy ◽

Multifrequency Bioimpedance ◽

Study Population ◽

The Mean ◽

Main Factor

Objective: To analyze the concordance and agreement between bioimpedance spectroscopy (BIS) and anthropometry for the diagnosis of protein energy wasting (PEW) in chronic peritoneal dialysis patients.Methods: Prospective, multi-center, observational study using multifrequency bioimpedance device (Body Composition Monitor -BCM®- Fresenius Medical Care) and anthropometry for the diagnosis of PEW as recommended by the International Society of Renal Nutrition and Metabolism (ISRNM). Cohen's kappa was the main test used to analyze concordance and a Bland-Altmann curve was built to evaluate the agreement between both methods.Results: We included 137 patients from three PD clinics. The mean age of the study population was 57.7 ± 14.9, 47.8% had diabetes, and 52.2% were male. We calculated the scores for PEW diagnosis at 3 and 6 months after the first collection (T3 and T6) and on average 40% of the study population were diagnosed with PEW. The concordance in the diagnosis of PEW was only moderate between anthropometry and BIS at both T3 and T6. The main factor responsible for our results was a low to moderate correlation for muscle mass in kilograms, with an r-squared (R2) of 0.35. The agreement was poor, with a difference of more than 10 kg of muscle mass on average and with more than a quarter of all cases beyond the limits of agreements.Conclusion: Current diagnosis of PEW may differ depending on the tools used to measure muscle mass in peritoneal dialysis patients.

Download Full-text

MO752EVALUATION AND ANALYSIS OF CHRONIC PAIN IN HEMODIALYSIS PATIENTS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfab097.0032 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

Sanae Ezzaki ◽

Imane Failal ◽

Rania Elafifi ◽

Salma siham Elkhayat ◽

Ghizlane Medkouri ◽

...

Keyword(s):

Chronic Pain ◽

Cross Sectional Study ◽

Hemodialysis Patients ◽

Chronic Hemodialysis ◽

Advanced Age ◽

Dialysis Patients ◽

Cross Sectional ◽

High Prevalence ◽

Significant Intensity

Abstract Background and Aims Despite progress these recent years in support the hemodialysis, chronic pain remains a problem concern that ultimately affect the quality of life and psycho-emotional state, even among dialysis patients already psychologically fragile. However, it is often overlooked and its characteristics in chronic hemodialysis (HDC) are poorly understood. The purpose of this study was to evaluate the prevalence, features, impact and treatment of pain in our population of chronic hemodialysis patients and to determine the factors associated with it. Method cross-sectional study conducted in January 2020 including 71 chronic hemodialysis patients from the nephrology department of the CHU ibn rochd CASABLANCA. They were subjected to a questionnaire on socio-demographic characteristics, the characteristics of the pain, its impact on daily life, the various treatments performed. The pain is chronic if it persists for more than 3 months. The intensity was assessed using a visual analog scale. Results Of the 71 patients, 64.4% report chronic pain, the average age of our patients was 46.5 years, ranging from 16 to 93 years, with a sex ratio M/F 1.1, seniority hemodialysis was 17.3 years. The pain is continuous, frequent, intermittent and rare in respectively 55.5%, 27.5%, 13.7%, 3.44% of cases, it is a weak, moderate, severe, very severe in respectively: 13.7%, 58.6%, 17.24%, 10.3%, causing musculoskeletal was predominant in 75.8% of cases, the most common sites are: shoulders (47,23%), knees (34.5%), the head (41.2%) and the back (19.65%). It resounded on the patient's daily activity in 55.17%, and sleep in 41.3%, the treatment was essentially based analgesics in 58.6% of cases, these analgesics were level 1 in 47.1% cases and level 2 in 52.9% of cases. This is taken daily in 28.5% of patients, common in 42.8% and 28.5% rare among of them, the disappearance of pain was achieved in 65.51% of cases. In perdialyse, the intensity of the pain does not change in 79.4% of patients. Pain was favored by advanced age and age dialysis (advanced age (p = 0.043) and age dialysis (p = 0.01).) Conclusion Chronic pain is a major problem in hemodialysis by its high prevalence, its significant intensity and its impact on life daily patient. However its management remains inadequate. Regular assessment of pain using a well-codified questionnaire is necessary to improve the care of dialysis patients.

Download Full-text

Effects of Beraprost Sodium, An Oral Prostaglandin I2 Analog, on Hemostatic Factors and Inflammation in Chronic Peritoneal Dialysis Patients

Peritoneal Dialysis International ◽

10.1177/089686080902900212 ◽

2009 ◽

Vol 29 (2) ◽

pp. 178-181 ◽

Cited By ~ 5

Author(s):

Kyung Min Kim ◽

Hyun Woo Kim ◽

Jang Han Lee ◽

Jai Won Chang ◽

Jung Sik Park ◽

...

Keyword(s):

Peritoneal Dialysis ◽

Troponin T ◽

Density Lipoprotein ◽

High Sensitivity ◽

Endothelial Injury ◽

Apolipoprotein A1 ◽

Chronic Peritoneal Dialysis ◽

Prostaglandin I2 ◽

Dialysis Patients ◽

Beraprost Sodium

Beraprost sodium, an orally active prostaglandin I2 analog with vasodilatory, cytoprotective, antiplatelet, antithrombotic, and anti-inflammatory effects, 120 μg daily for 8 weeks, decreased plasma D-dimer, a marker of intravascular coagulation, and von Willebrand factor, a marker for endothelial injury, in 100 chronic peritoneal dialysis patients. Total cholesterol, triglycerides, high-density lipoprotein, apolipoprotein A1, apolipoprotein B, albumin, prealbumin, fibrinogen, troponin-T, and high-sensitivity C-reactive protein levels were not changed. Three patients complained of headache and 1 patient experienced facial flushing; however, no serious adverse effects were observed. These results suggest that beraprost sodium is effective in partially reversing the thrombogenic coagulation profile and endothelial injury in chronic peritoneal dialysis patients.

Download Full-text

Effects of Sulodexide on Hemostatic Factors, Lipid Profile, and Inflammation in Chronic Peritoneal Dialysis Patients

Peritoneal Dialysis International ◽

10.1177/089686080702700415 ◽

2007 ◽

Vol 27 (4) ◽

pp. 456-460 ◽

Cited By ~ 6

Author(s):

Soon Bae Kim ◽

Su Hee Kim ◽

Moo Song Lee ◽

Jai Won Chang ◽

Sang Koo Lee ◽

...

Keyword(s):

Peritoneal Dialysis ◽

Dermatan Sulfate ◽

High Sensitivity ◽

Blood Levels ◽

Chronic Peritoneal Dialysis ◽

Dialysis Patients ◽

Reactive Protein ◽

Hemostatic Factors ◽

Bleeding Episodes ◽

Von Willebrand

Sulodexide, a standardized extractive glycosaminoglycan containing 80% “fast moving” heparin and 20% dermatan sulfate, decreased plasma D-dimer, a marker of intravascular coagulation, and fibrinogen levels in chronic peritoneal dialysis patients. Blood levels of von Willebrand factor, lipid, and high-sensitivity C-reactive protein were not significantly changed. No bleeding episodes were reported. These results suggest that sulodexide was effective in partially reversing the thrombogenic coagulation profile without increasing the risk of bleeding.

Download Full-text